Quince Therapeutics, Inc.
US ˙ NasdaqGS ˙ US22053A1079

Introduction

This page provides a comprehensive analysis of the known insider trading history of David Lamond. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate David Lamond has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:QNCX / Quince Therapeutics, Inc. Director 2,347,545
US:AMTI / Applied Molecular Transport Inc. Director 20,000
US:LHDX / Lucira Health Inc Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David Lamond. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases QNCX / Quince Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in QNCX / Quince Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2023-12-14 QNCX Lamond David 22,627 1.0400 22,627 1.0400 23,532 355 2.1600 25,342 107.69
2023-12-13 QNCX Lamond David 22,627 1.0000 22,627 1.0000 22,627
2023-12-12 QNCX Lamond David 300 1.0000 300 1.0000 300
2023-12-12 QNCX Lamond David 22,327 1.0200 22,327 1.0200 22,774
2023-12-07 QNCX Lamond David 19,123 1.0100 19,123 1.0100 19,314
2023-12-06 QNCX Lamond David 19,123 1.0200 19,123 1.0200 19,505
2023-12-05 QNCX Lamond David 19,123 1.0100 19,123 1.0100 19,314
2023-12-01 QNCX Lamond David 14,378 0.9400 14,378 0.9400 13,515
2023-11-30 QNCX Lamond David 14,378 0.9000 14,378 0.9000 12,940
2023-11-29 QNCX Lamond David 14,378 0.9800 14,378 0.9800 14,090
2023-08-31 QNCX Lamond David 41,026 1.3200 41,026 1.3200 54,154
2023-08-30 QNCX Lamond David 41,026 1.3100 41,026 1.3100 53,744
2023-08-17 QNCX Lamond David 24,766 1.2900 24,766 1.2900 31,948
2023-08-16 QNCX Lamond David 117,348 1.2900 117,348 1.2900 151,379
2023-08-15 QNCX Lamond David 107,886 1.3200 107,886 1.3200 142,410
2021-03-24 CRTX Lamond David 50,000 33.7700 50,000 33.7700 1,688,500
2021-03-04 CRTX Lamond David 16,621 34.2800 16,621 34.2800 569,768
2021-03-04 CRTX Lamond David 13,310 35.0000 13,310 35.0000 465,850
2021-03-04 CRTX Lamond David 15,969 36.3400 15,969 36.3400 580,313
2021-03-04 CRTX Lamond David 4,100 36.8600 4,100 36.8600 151,126
2020-06-04 CRTX Lamond David 13,609 42.1322 13,609 42.1322 573,377
2020-06-04 CRTX Lamond David 10,642 43.3221 10,642 43.3221 461,034
2020-06-04 CRTX Lamond David 24,874 43.8765 24,874 43.8765 1,091,384
2020-05-19 CRTX Lamond David 400 54.0900 400 54.0900 21,636
2020-05-19 CRTX Lamond David 5,906 55.4197 5,906 55.4197 327,309
2020-05-19 CRTX Lamond David 32,894 56.4157 32,894 56.4157 1,855,738
2020-05-15 CRTX Lamond David 1,263 46.3007 1,263 46.3007 58,478
2020-05-15 CRTX Lamond David 985 48.3650 985 48.3650 47,640
2020-05-15 CRTX Lamond David 1,600 48.9584 1,600 48.9584 78,333
2020-05-15 CRTX Lamond David 1,000 50.7073 1,000 50.7073 50,707
2020-05-15 CRTX Lamond David 500 52.2010 500 52.2010 26,100
2020-05-15 CRTX Lamond David 100 53.1000 100 53.1000 5,310

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

QNCX / Quince Therapeutics, Inc. Insider Trades
Insider Sales QNCX / Quince Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in QNCX / Quince Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

QNCX / Quince Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by David Lamond as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2023-12-14 2023-12-14 4 QNCX Quince Therapeutics, Inc.
Common Stock 		P - Purchase 22,627 2,347,545 0.97 1.04 23,532 2,441,447
2023-12-14 2023-12-13 4 QNCX Quince Therapeutics, Inc.
Common Stock 		P - Purchase 22,627 2,324,918 0.98 1.00 22,627 2,324,918
2023-12-14 2023-12-12 4 QNCX Quince Therapeutics, Inc.
Common Stock 		P - Purchase 22,327 2,302,291 0.98 1.02 22,774 2,348,337
2023-12-14 2023-12-12 4 QNCX Quince Therapeutics, Inc.
Common Stock 		P - Purchase 300 2,279,964 0.01 1.00 300 2,279,964
2023-12-07 2023-12-07 4 QNCX Quince Therapeutics, Inc.
Common Stock 		P - Purchase 19,123 2,279,664 0.85 1.01 19,314 2,302,461
2023-12-07 2023-12-06 4 QNCX Quince Therapeutics, Inc.
Common Stock 		P - Purchase 19,123 2,260,541 0.85 1.02 19,505 2,305,752
2023-12-07 2023-12-05 4 QNCX Quince Therapeutics, Inc.
Common Stock 		P - Purchase 19,123 2,241,418 0.86 1.01 19,314 2,263,832
2023-12-01 2023-12-01 4 QNCX Quince Therapeutics, Inc.
Common Stock 		P - Purchase 14,378 2,222,295 0.65 0.94 13,515 2,088,957
2023-12-01 2023-11-30 4 QNCX Quince Therapeutics, Inc.
Common Stock 		P - Purchase 14,378 2,207,917 0.66 0.90 12,940 1,987,125
2023-12-01 2023-11-29 4 QNCX Quince Therapeutics, Inc.
Common Stock 		P - Purchase 14,378 2,193,539 0.66 0.98 14,090 2,149,668
2023-08-31 2023-08-31 4 QNCX Quince Therapeutics, Inc.
Common Stock 		P - Purchase 41,026 2,179,161 1.92 1.32 54,154 2,876,493
2023-08-31 2023-08-30 4 QNCX Quince Therapeutics, Inc.
Common Stock 		P - Purchase 41,026 2,138,135 1.96 1.31 53,744 2,800,957
2023-08-17 2023-08-17 4 QNCX Quince Therapeutics, Inc.
Common Stock 		P - Purchase 24,766 2,097,109 1.20 1.29 31,948 2,705,271
2023-08-17 2023-08-16 4 QNCX Quince Therapeutics, Inc.
Common Stock 		P - Purchase 117,348 2,072,343 6.00 1.29 151,379 2,673,322
2023-08-17 2023-08-15 4 QNCX Quince Therapeutics, Inc.
Common Stock 		P - Purchase 107,886 1,954,995 5.84 1.32 142,410 2,580,593
2022-05-26 2022-05-24 4 AMTI Applied Molecular Transport Inc.
Stock Option (Right to Buy) 		A - Award 20,000 20,000
2022-05-23 2022-05-23 4 AMTI Applied Molecular Transport Inc.
Common Stock 		P - Purchase 33,500 1,077,519 3.21 3.26 109,210 3,512,712
2022-05-23 2022-05-20 4 AMTI Applied Molecular Transport Inc.
Common Stock 		P - Purchase 33,000 1,044,019 3.26 3.08 101,640 3,215,579
2022-05-23 2022-05-19 4 CRTX Cortexyme, Inc.
Common Stock 		A - Award 200,002 1,734,722 13.03
2021-06-17 2021-06-16 4 CRTX Cortexyme, Inc.
Stock Option (right to buy) 		A - Award 11,029 11,029
2021-05-20 2021-05-18 4 AMTI Applied Molecular Transport Inc.
Stock Option (Right to Buy) 		A - Award 15,175 15,175
2021-04-07 2021-04-06 4 AMTI Applied Molecular Transport Inc.
Common Stock 		P - Purchase 25,000 1,011,019 2.54 42.00 1,050,000 42,462,798
2021-03-24 2021-03-24 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 50,000 1,847,109 2.78 33.77 1,688,500 62,376,871
2021-03-23 2021-03-04 4 CRTX Cortexyme, Inc.
Common Stock 		G - Gift 1,534,720 1,534,720
2021-03-05 2021-03-04 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 4,100 1,797,109 0.23 36.86 151,126 66,241,438
2021-03-05 2021-03-04 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 15,969 1,793,009 0.90 36.34 580,313 65,157,947
2021-03-05 2021-03-04 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 13,310 1,777,040 0.75 35.00 465,850 62,196,400
2021-03-05 2021-03-04 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 16,621 1,763,730 0.95 34.28 569,768 60,460,664
2021-02-09 2021-02-09 4 LHDX Lucira Health, Inc.
Series C Preferred Stock 		C - Conversion -92,756 0 -100.00
2021-02-09 2021-02-09 4 LHDX Lucira Health, Inc.
Series B Preferred Stock 		C - Conversion -53,629 0 -100.00
2021-02-09 2021-02-09 4 LHDX Lucira Health, Inc.
Common Stock 		C - Conversion 92,756 146,385 172.96
2021-02-09 2021-02-09 4 LHDX Lucira Health, Inc.
Common Stock 		C - Conversion 53,629 53,629
2021-02-04 3 LHDX Lucira Health, Inc.
Common Stock 		125,281
2020-06-11 2020-06-09 4 AMTI Applied Molecular Transport Inc.
Series A Preferred Stock 		C - Conversion -1 0 -100.00
2020-06-11 2020-06-09 4 AMTI Applied Molecular Transport Inc.
Series C Preferred Stock 		C - Conversion -1 0 -100.00
2020-06-11 2020-06-09 4 AMTI Applied Molecular Transport Inc.
Series B Preferred Stock 		C - Conversion -1 0 -100.00
2020-06-11 2020-06-09 4 AMTI Applied Molecular Transport Inc.
Common Stock 		A - Award 71,430 986,019 7.81 14.00 1,000,020 13,804,266
2020-06-11 2020-06-09 4 AMTI Applied Molecular Transport Inc.
Common Stock 		C - Conversion 914,589 914,589
2020-06-09 2020-06-08 4 CRTX Cortexyme, Inc.
Stock Option (Right to Buy) 		A - Award 11,029 11,029
2020-06-08 2020-06-04 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 24,874 1,747,109 1.44 43.88 1,091,384 76,657,028
2020-06-08 2020-06-04 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 10,642 1,722,235 0.62 43.32 461,034 74,610,837
2020-06-08 2020-06-04 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 13,609 1,711,593 0.80 42.13 573,377 72,113,179
2020-05-19 2020-05-19 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 32,894 1,697,984 1.98 56.42 1,855,738 95,792,956
2020-05-19 2020-05-19 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 5,906 1,665,090 0.36 55.42 327,309 92,278,788
2020-05-19 2020-05-19 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 400 1,659,184 0.02 54.09 21,636 89,745,263
2020-05-19 2020-05-15 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 100 1,658,784 0.01 53.10 5,310 88,081,430
2020-05-19 2020-05-15 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 500 1,658,684 0.03 52.20 26,100 86,584,963
2020-05-19 2020-05-15 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 1,000 1,658,184 0.06 50.71 50,707 84,082,034
2020-05-19 2020-05-15 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 1,600 1,657,184 0.10 48.96 78,333 81,133,077
2020-05-19 2020-05-15 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 985 1,655,584 0.06 48.36 47,640 80,072,320
2020-05-19 2020-05-15 4 CRTX Cortexyme, Inc.
Common Stock 		P - Purchase 1,263 1,654,599 0.08 46.30 58,478 76,609,092
2020-02-10 2020-02-10 4 CRTX Cortexyme, Inc.
Common Stock 		A - Award 30,000 1,653,336 1.85 50.00 1,500,000 82,666,800
2019-05-13 2019-05-13 4 CRTX Cortexyme, Inc.
Series B Redeemable Convertible Preferred Stock 		C - Conversion -924,056 0 -100.00
2019-05-13 2019-05-13 4 CRTX Cortexyme, Inc.
Series A Redeemable Convertible Preferred Stock 		C - Conversion -301,829 0 -100.00
2019-05-13 2019-05-13 4 CRTX Cortexyme, Inc.
Series A Redeemable Convertible Preferred Stock 		C - Conversion -699,280 0 -100.00
2019-05-13 2019-05-13 4 CRTX Cortexyme, Inc.
Common Stock 		C - Conversion 301,829 301,829
2019-05-13 2019-05-13 4 CRTX Cortexyme, Inc.
Common Stock 		C - Conversion 1,623,336 1,623,336
2019-05-08 3 CRTX Cortexyme, Inc.
Common Stock 		0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)